Laboratory Bergamo

Laboratório Bergamo is a Brazilian pharmaceutical company that specializes in the development, manufacturing, and commercialization of high-complexity medicines, with a primary focus on oncology and hematology. Founded in 1946, the company established itself as a leader in the Brazilian institutional market, providing essential treatments for cancer and other serious conditions. In 2011, Bergamo was acquired by Amgen, serving as a strategic entry point for the global biotechnology giant into the Brazilian market. Today, it operates as a subsidiary of Amgen, maintaining manufacturing facilities in Taboão da Serra and distributing a portfolio that includes both generic and branded specialty pharmaceuticals.